Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 12;10(1):27.
doi: 10.1186/s40942-024-00543-7.

Serum adropin level in wet-type age-related macular degeneration

Zahra Saeedi-Maleki  1   2 , Alireza Javadzadeh  3 , Fariborz Brumandpur  1 , Amir Ghorbanihaghjo  3 , Shokoufeh Khanzadeh  4 , Farideh Mousavi  5
Affiliations

Serum adropin level in wet-type age-related macular degeneration

Zahra Saeedi-Maleki et al. Int J Retina Vitreous. .

Abstract

Purpose: Our objective was to compare the serum Adropin levels between patients with wet-type Age-Related Macular Degeneration (AMD) and otherwise healthy individuals.

Method: The study included 45 patients with wet-type AMD and 45 individuals without age-related macular degeneration. Patients with co-morbidities such as diabetes, hypertension, autoimmune diseases, and a previous history of visual impairment; were excluded. FBS, Hemoglobin A1C (HbA1C), lipid profile, and serum Adropin level were checked.

Results: The mean serum Adropin level of patients with wet-type AMD was significantly lower than the control group (P-value < 0.001). Also, the mean High-sensitivity C-reactive protein ( hsCRP) level and High Density Lipoprotein (HDL) were significantly higher in wet-type AMD patients (P-value = 0.031 and < 0.001 respectively).

Conclusions: In our study, wet-type AMD was associated with a lower level of serum Adropin. Because of Adropin involvement in glucose metabolism and age-related changes, it may have a role in the pathogenesis of AMD, but it requires more investigations at the molecular level to elucidate its function.

Keywords: Adropin; Age-related macular degeneration; High-Density Lipoprotein.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Eng KT, Kertes PJ. Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging. 2006;1(4):451–66. doi: 10.2147/ciia.2006.1.4.451. - DOI - PMC - PubMed
    1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44. doi: 10.1056/NEJMoa062655. - DOI - PubMed
    1. Coleman HR, Chan CC, Ferris FL, 3rd, Chew EY. Age-related macular degeneration. Lancet. 2008;372(9652):1835–45. doi: 10.1016/S0140-6736(08)61759-6. - DOI - PMC - PubMed
    1. Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640–2. doi: 10.1001/archopht.1984.01040031330019. - DOI - PubMed
    1. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108(4):697–704. doi: 10.1016/S0161-6420(00)00580-7. - DOI - PubMed